We are live on ! Find out more
ARIA

Ariad Pharmaceuticals Inc
ARIA

Delisted

ARIA was delisted on the 15th of February, 2017.

208 hedge funds and large institutions have $2.85B invested in Ariad Pharmaceuticals Inc in 2013 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 83 increasing their positions, 62 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

62% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 21

34% more repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 62

6% more capital invested

Capital invested by funds: $2.69B → $2.85B (+$164M)

5% more funds holding

Funds holding: 198208 (+10)

43% less call options, than puts

Call options by funds: $21.9M | Put options by funds: $38.3M

60% less funds holding in top 10

Funds holding in top 10: 52 (-3)

Holders
208
Holders Change
+10
Holders Change %
+5.05%
% of All Funds
6.74%
Holding in Top 10
2
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-60%
% of All Funds
0.06%
New
34
Increased
83
Reduced
62
Closed
21
Calls
$21.9M
Puts
$38.3M
Net Calls
-$16.4M
Net Calls Change
-$16.5M
Name Holding Trade Value Shares
Change
Change in
Stake
CLM
26
ClearBridge LLC (Maryland)
Maryland
$28.6M -$4.14M -213,384 -12%
BBA
27
Baker Bros. Advisors
New York
$24.5M -$2.26M -116,297 -8%
JHIU
28
Janus Henderson Investors US
Colorado
$24.4M -$55.7M -2,867,696 -68%
RG
29
Redmile Group
California
$23.3M -$254K -13,100 -1%
DM
30
Deerfield Management
New York
$22.6M -$736K -37,900 -3%
Adage Capital Partners
31
Adage Capital Partners
Massachusetts
$19.7M -$30.1M -1,550,000 -59%
Brown Advisory
32
Brown Advisory
Maryland
$19.5M +$2.2M +113,537 +12%
TCIM
33
TIAA CREF Investment Management
New York
$19.1M -$5.47M -281,746 -21%
Morgan Stanley
34
Morgan Stanley
New York
$18.6M +$8.46M +435,511 +75%
O
35
OppenheimerFunds
New York
$18.4M
American Century Companies
36
American Century Companies
Missouri
$16.9M +$17.4M +896,430 +3,625%
Jennison Associates
37
Jennison Associates
New York
$16.4M -$25.5M -1,314,826 -60%
Geode Capital Management
38
Geode Capital Management
Massachusetts
$14.8M +$1.1M +56,822 +8%
Bank of New York Mellon
39
Bank of New York Mellon
New York
$14.7M -$685K -35,277 -4%
Northern Trust
40
Northern Trust
Illinois
$14.3M -$1.01M -52,148 -6%
VAM
41
Visium Asset Management
New York
$13.9M +$14.6M +754,156 New
Lazard Asset Management
42
Lazard Asset Management
New York
$13.8M -$754K -38,830 -5%
Millennium Management
43
Millennium Management
New York
$12.6M +$12.2M +627,501 +1,135%
JP Morgan Chase
44
JP Morgan Chase
New York
$12.4M +$253K +13,025 +2%
BG
45
BlackRock Group
United Kingdom
$10.8M +$8.1M +417,330 +244%
Axa
46
Axa
France
$10.7M +$1.23M +63,591 +12%
IIM
47
Ironwood Investment Management
Massachusetts
$10.6M +$218K +11,239 +2%
PCM
48
Palisade Capital Management
New Jersey
$10.1M -$836K -43,039 -7%
CCP
49
Clough Capital Partners
Massachusetts
$9.95M +$5.57M +286,800 +113%
OAM
50
Oxford Asset Management
United Kingdom
$9.87M +$6.37M +328,091 +158%

ARIA Hedge Fund Activity: Q3 2013 in Review

208 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Ariad Pharmaceuticals Inc (ARIA) for Q3 2013, worth a combined $2.85B — up 6.1% from $2.69B a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new ARIA positions and 21 closed out — a net gain of 13 holders — while 83 added to existing stakes and 62 trimmed.

The largest buyer was Franklin Resources, adding an estimated $64.5M. The largest seller was Artisan Partners, cutting an estimated $135M.

  • 208 institutional investors held Ariad Pharmaceuticals Inc (ARIA) as of Q3 2013, up from 198 in Q2 2013.
  • Funds reported $2.85B of Ariad Pharmaceuticals Inc stock for Q3 2013, up 6.1% quarter-over-quarter.
  • 34 funds opened new Ariad Pharmaceuticals Inc positions in Q3 2013 and 21 closed out, a net change of +13 holders.
  • The largest Ariad Pharmaceuticals Inc buyer in Q3 2013 was Franklin Resources, an estimated $64.5M added.
  • The largest Ariad Pharmaceuticals Inc seller in Q3 2013 was Artisan Partners, an estimated $135M sold.

Based on aggregated 13F filings for Q3 2013.